Evidence map›Paper›PMID 30367332›Full record

ArticleBreast cancer research and treatment2019

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth.

Laura W Bowers, Claire G Lineberger, Nikki A Ford, Emily L Rossi, Arunima Punjala, Kristina K Camp, Bruce K Kimler, Carol J Fabian, Stephen D Hursting

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Flax Lignans: From Biosynthetic Regulation to Biological Activities.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Lignans: Advances in Biosynthesis, Bioavailability, and Pharmacological Activity.Combinatorial chemistry & high throughput screening · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Iranian journal of medical sciences · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Pharmaceutical biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Laura W BowersDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA.ORCID http://orcid.org/0000-0002-7922-4167
Claire G LinebergerDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA.
Nikki A FordDepartment of Nutritional Sciences, University of Texas at Austin, 1400 Barbara Jordan Blvd, R1800, Austin, TX, 78723, USA.
Emily L RossiDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA.
Arunima PunjalaDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA.
Kristina K CampDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA.
Bruce K KimlerDepartment of Radiation Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
Carol J FabianDepartment of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
Stephen D HurstingDepartment of Nutrition, University of North Carolina, 135 Dauer Drive, CB #7461, Chapel Hill, NC, 27599, USA. hursting@email.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Kansas Medical Center · USThe University of Texas at Austin · US

Funding

UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUSAN M. SMITH · 1999 to 2026
$31.6M
LINEBERGER CANCER CONTROL EDUCATION PROGRAMR25CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EARP, JO ANNE L, RIBISL, KURT M. · 1992 to 2016
$8.0M
Higher Dietary Carbohydrates Detrimentally Impact Obesity-Associated Breast Cancer ChemoresistanceR35CA197627 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HURSTING, STEPHEN D · 2015 to 2021
$6.0M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Enhancement Training for the Next Generation of Translational Ph.D. ScientistsT32GM122741 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S., YEH, JEN JEN · 2018 to 2022
$898k
Breast Cancer Research Foundation BCRF 16-075NCI NIH HHS R25 CA057726NCI NIH HHS R35 CA197627NCI NIH HHS R35CA197627NCI NIH HHS T32 CA057726NIDDK NIH HHS P30 DK056350NIGMS NIH HHS T32 GM122741Susan G. Komen KG101039
6 · The paper itself

Abstract

purposeExposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear.

methodsC57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG's anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively.

resultsSDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL's inhibition of E0771 cell viability and survival.

conclusionsSDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use.

Indexed as

4-ButyrolactoneAnimalsAnti-Inflammatory AgentsBiomarkersButylene GlycolsCell Line, TumorCell SurvivalCytokinesDisease Models, AnimalDose-Response Relationship, DrugFemaleFlaxGene Expression ProfilingGlucosidesImmunohistochemistryLignans2,3-bis(3'-hydroxybenzyl)butyrolactone4-ButyrolactoneAnti-Inflammatory AgentsBiomarkersButylene GlycolsCytokinesGlucosidesLignansNF-kappa Bsecoisolariciresinol diglucosideBreast cancerEnterodiol (END)Enterolactone (ENL)NFκBPlant lignanSecoisolariciresinol diglucoside (SDG)

Identifiers

PMID30367332
PMCPMC6394576
OpenAlexW2898436330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.